Compare TTEK & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | RDY |
|---|---|---|
| Founded | 1966 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.9B |
| IPO Year | 1995 | 2001 |
| Metric | TTEK | RDY |
|---|---|---|
| Price | $33.72 | $12.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $40.33 | $13.31 |
| AVG Volume (30 Days) | 1.7M | ★ 2.5M |
| Earning Date | 11-11-2026 | 10-23-2026 |
| Dividend Yield | ★ 0.87% | 0.51% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $2,964,148,000.00 | N/A |
| Revenue This Year | N/A | $4.73 |
| Revenue Next Year | $4.35 | $11.63 |
| P/E Ratio | $28.45 | ★ $18.67 |
| Revenue Growth | ★ 7.66 | N/A |
| 52 Week Low | $25.81 | $11.36 |
| 52 Week High | $43.14 | $15.67 |
| Indicator | TTEK | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 54.62 |
| Support Level | $33.25 | $12.09 |
| Resistance Level | $34.29 | $12.48 |
| Average True Range (ATR) | 0.95 | 0.21 |
| MACD | -0.36 | 0.07 |
| Stochastic Oscillator | 11.47 | 64.87 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.